Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

August 5, 2019August 5, 2019

Mortality Rate Due to IPF Has Risen in United Kingdom, Data Show

News

The mortality rate due to idiopathic pulmonary fibrosis (IPF) increased from 1979 to 2016 in the United Kingdom, a retrospective analysis shows. Researchers estimate that death due to IPF ... Read more

July 31, 2019August 2, 2019

New Clinical Model to Manage Terminally Ill IPF Patients Decreases Suffering and Costs

News

A new clinical model for terminal idiopathic pulmonary fibrosis (IPF) that allows patients to receive treatment at home has increased patient satisfaction, decreased hospital deaths, led to better symptom ... Read more

July 26, 2019July 26, 2019

Certain Matrix Metalloproteinases Are Potential Biomarkers for PF in Rare Genetic Disorder, Study Suggests

News

Increased activity of certain matrix metalloproteinases (MMPs), enzymes that regulate cell behavior, may explain the risk for developing aggressive pulmonary fibrosis in people with Hermansky-Pudlak syndrome (HPS), a rare ... Read more

July 17, 2019July 17, 2019

IPF Patients Older Than 75 More Likely to Stop Taking Esbriet Because of Adverse Reactions, Japanese Study Suggests

News

Patients older than 75 with idiopathic pulmonary fibrosis (IPF) are at higher risk of discontinuing treatment with Esbriet (pirfenidone) due to adverse reactions, namely anorexia, according to a retrospective analysis made ... Read more

July 16, 2019July 16, 2019

Gilead Sciences Gains Rights to GLPG1690 Clinical Program in 10-year Research Collaboration

News

Gilead Sciences gained rights over GLPG1690, Galapagos‘ investigational therapy for idiopathic pulmonary fibrosis (IPF), as part of a 10-year research collaboration between the two companies. The agreement will allow Gilead to ... Read more

June 25, 2019June 25, 2019

Genetic Variants of MUC5AC Gene May Be a Risk Factor for IPF, Study Suggests

News

Genetic variants of the MUC5AC gene may contribute to the development of idiopathic pulmonary fibrosis (IPF), a study suggests. The study, “Novel idiopathic pulmonary fibrosis susceptibility variants revealed by ... Read more

June 19, 2019June 21, 2019

Esbriet Helps Halt Breathlessness Symptoms in Severe IPF, Analysis of Multiple Trials Shows

Esbriet, News

Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF), a post-hoc analysis of the ASCEND and CAPACITY trials shows. The ... Read more

June 12, 2019June 12, 2019

Certain Blood Protein Levels May Predict Mortality Risk After Sudden Disease Worsening in IPF, Study Suggests

News

Increased levels of specific proteins found in blood, namely C-reactive protein, lactate dehydrogenase, and total cholesterol, may predict the risk of mortality after acute exacerbation in idiopathic pulmonary fibrosis ... Read more

May 21, 2019May 22, 2019

Experimental IPF Therapy Safe and Well-tolerated, Ongoing Phase 1 Study Shows

News

Bridge Biotherapeutics’ investigational therapeutic candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) was found to be safe and well-tolerated in the single-ascending dose phase of a Phase 1 trial with healthy volunteers, the ... Read more

May 10, 2019

Herbal Compound Rosavin May Help Reduce PF-related Scarring, Inflammation, Mouse Study Suggests

News

Rosavin, an active compound found in the plant Rhodiola rosea, commonly known as golden root or Aaron’s rod, can prevent pulmonary fibrosis (PF) manifestations in mice, a study has ... Read more

Pin It on Pinterest